EXEL
Exelixis, Inc.
Is EXEL Halal?
Oncology pharmaceuticals are generally permissible, but Exelixis's current marketable-securities liquidity ratio is above the examined asset-based Sharia limits.
What You Should Know
Exelixis's March 31, 2026 Form 10-Q reports $2,593.593 million of total assets, no reported interest-bearing debt, $226.152 million of cash, $1,200.199 million of marketable securities, $328.947 million of net trade receivables and $610.812 million of quarterly revenue. Those inputs produce debt/assets of 0.00%, liquidity of 55.00%, receivables plus cash/assets of 21.40% and disclosed interest income/revenue of 2.64%. The oncology-pharmaceutical business is generally permissible at the activity level, but the 55.00% liquidity ratio fails the examined FTSE Yasaar, MSCI and Malaysia asset-based limits. This is a current ZakatInvest calculation, not an index-membership claim.
⚠️ Concerns
- •Liquidity is 55.00% of total assets, above the examined 33% asset-based limits; the portfolio includes commercial paper, corporate bonds, U.S. government securities, municipal bonds, money-market funds and certificates of deposit
- •No interest-bearing debt is reported, but repurchases, acquisitions, clinical programs and marketable-securities deployment can materially change the screen
- •The filing reports $16.127 million of interest income, or 2.64% of revenue; no fixed scholar-approved purification rate is asserted
- •Cabozantinib products account for most current revenue, creating franchise concentration and patent-cycle risk
- •License, royalty and collaboration revenues involve Ipsen, Takeda, Genentech and other partners; contract-level terms and downstream use remain qualitative review topics
- •Clinical-trial outcomes, regulatory approvals, animal-derived research materials and product-access debates remain qualitative diligence topics
- •Market-cap denominator methods are not calculated without a licensed historical market-cap series
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.
0 / 2,593.593
1,426.351 / 2,593.593
555.099 / 2,593.593
16.127 / 610.812
- Financial
- Fails
- Overall
- Fails
Debt is 0.00%, receivables plus cash are 21.40% and disclosed interest income is 2.64%, but liquidity is 55.00%, above the examined 33.333% asset limit.
- Financial
- Fails
- Overall
- Fails
Debt and receivables plus cash pass the examined limits, but liquidity is 55.00%, above the examined MSCI 33.33% total-assets limit. This is a calculation against the named method, not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Debt is 0.00%, but identifiable interest-bearing liquidity is 55.00%, above the examined 33% Malaysia SAC financial limit. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Exelixis discovers, develops and commercializes medicines for difficult-to-treat cancers, including the cabozantinib franchise and pipeline assets. Pharmaceutical research, development and commercialization are generally permissible at the activity level.
Limitation: The filing provides product, collaboration and geographic revenue disclosures but does not provide a universal prohibited-revenue numerator by indication, customer, ingredient or end use, so no unsupported haram-revenue percentage is estimated.
Purification
Disclosed interest income is 2.64% of quarterly revenue and below the examined 5% income threshold, but no fixed scholar-approved purification rate is asserted and business-revenue allocation remains incomplete.
Inputs, assumptions and primary sources
- Assets use Exelixis' consolidated total assets of $2,593.593 million at March 31, 2026.
- No interest-bearing debt is reported on the condensed balance sheet. Operating lease liabilities and other non-current liabilities are not silently added as conventional debt.
- Interest-bearing securities use current marketable securities of $551.055 million plus non-current marketable securities of $649.144 million. These securities include commercial paper, corporate bonds, U.S. Treasury and government-sponsored enterprises, municipal bonds, money-market funds and certificates of deposit.
- Receivables use $328.947 million of net trade receivables; inventory and other current assets are not silently added.
- Quarterly revenue is $610.812 million for the three months ended March 31, 2026. The filing separately reports $16.127 million of interest income, or 2.64% of revenue.
- The oncology-pharmaceutical activity is generally permissible, but the filing does not allocate a universal prohibited-revenue numerator by indication, customer or end use.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →